Streetbeat News

Products Services

IONS

Ionis Pharmaceuticals announced that the Phase 3 Balance study of olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo. This news has led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:57 pm

CADL

Candel Therapeutics Inc (NASDAQ:CADL) has revealed updated activity data from its ongoing phase 2 trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor treatment in patients with non-resectable, stage III/IV non-small cell lung cancer. Of the 40 evaluable patients, 15 have lived ≥ 12 months; of these, 10 patients have lived > 18 months. Candel expects to share topline overall survival data for Cohort 2 in the second quarter of 2024. CADL shares are down 18.24% at $0.92 on the last check Tuesday.

Portfolio Pulse from Vandana Singh

September 26, 2023 | 4:46 pm

OMGA

Omega Therapeutics Inc (NASDAQ:OMGA) announced preliminary data from its Phase 1/2 MYCHELANGELO I study of OTX-2002 in liver cancer and other solid tumors. The data showed encouraging anti-tumor activity, with on-target engagement and intended epigenetic changes observed in all patients. OTX-2002 was generally well tolerated, with no dose-limiting toxicities. Despite the positive news, OMGA shares are down 14.70% at $2.56.

Portfolio Pulse from Vandana Singh

September 26, 2023 | 4:41 pm

XPEV

Chinese electric vehicle (EV) manufacturer XPeng Inc. has reportedly started shipping 750 G9 SUVs and P7 sedans to Israel, marking its largest single shipment to an international market. The vehicles are expected to officially enter the Israeli market in October through regional dealership Freesbe. This is the company's second vehicle shipment to Israel within this month. XPeng's shares are trading lower by 0.36% to $16.63 on Tuesday.

Portfolio Pulse from Nabaparna Bhattacharya

September 26, 2023 | 4:40 pm

VERV

Verve Therapeutics announced it will present interim data from its ongoing heart-1 Phase 1b clinical trial of VERVE-101 at the American Heart Association's Scientific Sessions 2023 in November. This news has led to an increase in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:33 pm

FSR

Fisker Inc. (NYSE:FSR) plans to increase its deliveries to 300 vehicles daily in both the U.S. and European markets by the end of the year. The company has already produced 5,000 units of the Fisker Ocean SUV, with over 900 vehicles already delivered to customers. FSR shares are trading higher by 16.48% at $6.18.

Portfolio Pulse from Akanksha Bakshi

September 26, 2023 | 4:28 pm

OCUP

Ocuphire Pharma Inc has received New Drug Application (NDA) approval from the FDA for RYZUMVI Type 3, a new dosage form of the drug.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:13 pm

DMK

DMK Pharmaceuticals Corporation has been granted patent number 3061323 for an opioid designed to reduce and/or treat drug addiction.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:10 pm

SAP

SAP has announced a new generative AI assistant named Joule. The AI assistant is built directly into the solutions that power mission-critical processes, acting as a copilot that truly understands business.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2023 | 4:02 pm